



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12P 21/00, C12N 5/00 A61K 39/395	A1	(11) International Publication Number: WO 91/00360 (43) International Publication Date: 10 January 1991 (10.01.91)
--	----	---

(21) International Application Number: PCT/US90/03751

(22) International Filing Date: 29 June 1990 (29.06.90)

(30) Priority data:
373,905 29 June 1989 (29.06.89) US(71) Applicant: MEDAREX, INC. [US/US]; 20 Nassau Street,
Princeton, NJ 08542 (US).(72) Inventors: FANGER, Michael, W. ; West View Lane, Box
421, Lebanon, NH 03766 (US). GUYRE, Paul, M. ;
Pinneo Hill Road, Hanover, NH 03755 (US). DINCES,
Nathan, B. ; R.R. #2, Box 924, Canaan, NH 03741 (US).(74) Agents: BROOK, David, E. et al.; Hamilton, Brook, Smith
& Reynolds, Two Militia Drive, Lexington, MA 02173
(US).(81) Designated States: AT (European patent), AU, BE (Euro-
pean patent), CA, CH (European patent), DE (Euro-
pean patent)*, DK (European patent), ES (European pa-
tent), FI, FR (European patent), GB (European patent),
IT (European patent), JP, LU (European patent), NL
(European patent), NO, SE (European patent).**Published***With international search report.**Before the expiration of the time limit for amending the
claims and to be republished in the event of the receipt of
amendments.*

(54) Title: BISPECIFIC REAGENTS FOR AIDS THERAPY

(57) Abstract

Bispecific molecules which react both with the high-affinity Fcγ receptor of human effector cells and with a virus or virus component are disclosed. Binding of the molecules to the Fc receptors found on effector cells is not blocked by human immunoglobulin G. The molecules are useful for targeting human effector cells (e.g. macrophages) against a viral target (e.g. HIV or HIV-infected cell). For this purpose, bispecific molecules can be constructed containing the binding region derived from an anti-Fcγ receptor antibody and the CD4 molecule or CD4 binding domain of the envelope glycoprotein gp120 of HIV. Alternatively, bispecific antibodies or heteroantibodies can be constructed containing the binding region derived from an anti-Fc receptor antibody and the binding region of a HIV-specific antibody such as anti-gp120 antibody. Targeted effector cells can be used to kill virus by cell mediated antibody dependent cytolysis.

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TC	Togo
DK	Denmark			US	United States of America

-1-

BISPECIFIC REAGENTS FOR AIDS THERAPYBackground

05 In the absence of an effective vaccine or
therapy, the incidence of acquired immune deficiency
syndrome (AIDS) in the United States and other
countries is likely to increase during the next few
years. Preventing infection with the human
immunodeficiency virus (HIV) will depend upon
education and counselling to prevent transmission
10 among the populations at risk for AIDS.

To date, neither active immunization with the
HIV envelope glycoprotein gp120 nor passive
immunization with AIDS-immune serum has protected
non-human primates from subsequent challenge with
15 AIDS. The prospects for effective immunization
against HIV infection are not encouraging at this
time.

Recently, the initial events in infection of
human T lymphocytes, macrophages, and other cells by
20 HIV have been elucidated. These events involve the
attachment of the HIV envelope glycoprotein gp120 to
its cellular receptor, CD4. Cells that lack CD4 are
not susceptible to HIV infection, but become suscep-
tible after they are transfected with the CD4 gene
25 and express CD4 on their surfaces. This information
has led to studies of the use of recombinant CD4
(rCD4) which might be used therapeutically to block
the CD4-binding sites on HIV, preventing it from
binding to CD4 on host cells. However, this would
30 provide only a passive blockage of virus infection,

-2-

and would not lead to active elimination of the virus.

A therapeutic approach has been developed to eliminate the virus. This involves linkage of CD4 to the Fc region of human IgG. Capon, D.J. *et al.*, Nature, 337, 525 (1989). The Fc region of human IgG is the natural ligand for receptors on monocytic cells. Moreover, in the Fc portion of IgG reside immunoglobulin functions such as Fc receptor binding, protein A binding and complement fixation. These properties of the Fc portion of human immunoglobulin are the major mechanisms for elimination of pathogens. Fc activates the complement pathway, resulting in lysis of the pathogen, whereas binding to the Fc cell receptors on effector cells can lead to ingestion of the pathogen by phagocytosis or lysis by killer cells.

Nevertheless, the vast amount and diversity of natural antibodies (i.e. non-HIV specific IgG) found in vivo remains a major obstacle to this kind of in vivo therapy since non-HIV specific IgG would be expected to block binding of the Fc region with Fc receptors. A need exists to develop a therapeutic modality that overcomes these problems.

25 Summary of the Invention

This invention pertains to bispecific molecules which can bind a pathogen and which can simultaneously target the pathogen and pathogen-infected cells for ingestion and destruction by effector cells such as monocytes, macrophages, and

-3-

n utrophils. The bispecific molecules of this invention have a first binding specificity for a pathogen (e.g. virus) and a second binding specificity for the high-affinity Fc γ receptor. The
05 binding specificity for the Fc γ receptor is for a site which is distinct from the ligand binding site for the Fc region of IgG. The bispecific molecules are capable of binding to IgG-occupied receptor of effector cells in the presence of normal serum IgG.

10 For example, if the target pathogen is a virus such as HIV, the targeted viral component can be the envelope glycoprotein gp120 of HIV. The binding specificity for gp120 can be provided in several ways. It can be provided by the CD4 molecule of T
15 cells or just the CD4 binding domain thereof. Alternatively, the gp120 specificity can be provided by a gp120-specific antibody. The binding specificity for the high affinity Fc γ receptor is provided by an antibody which binds to an epitope of the Fc
20 receptor, the binding of which is not blocked by human IgG.

The bispecific molecules of this invention can be administered alone or they can be pre-attached to effector cells for administration to the patient.
25 They can also be used in conjunction with other molecules. For example, molecules of this invention can be used with cytokines such as interferon- γ which can activate or enhance their therapeutic potential. The effector cells can be obtained from
30 the patient or from other sources so long as the cells are compatible with the patient's immune

-4-

syst m. The binding of bispecific molecule to the effector cell results in a targeted effector cell i.e., an effector cell with attached bispecific antibody or heteroantibody containing antigen
05 binding regions which are specific for a desired pathogen. The targeted effector cells can be used to bring about antibody dependent cell mediated cytotoxicity (ADCC) and/or phagocytosis of the target cells in vivo.

10 Detailed Description of the Invention

The bispecific molecules of this invention have at least two distinct binding specificities. The molecules contain a binding specificity for a pathogen such as a virus component, and a binding
15 specificity for the Fc γ receptor of effector cells.

The Fc-receptor binding specificity is provided by a binding agent which binds to the high affinity (p72) Fc γ receptor (FcRI) for human IgG without being blocked by human IgG. The preferred Fc γ
20 receptor binding agent is an antibody, antibody fragment, antibody variable region, or genetic construct having the following characteristics:

- a. it reacts specifically with the high affinity Fc γ receptor;
- 25 b. it reacts with the receptor through its antigen combining region independent of any Fc portion;
- c. it reacts with an epitope of Fc γ receptor which is distinct from the Fc binding (i.e. ligand
30 binding) site of the receptor; and
- d. it binds ligand-occupied receptor.

-5-

The anti-Fc γ receptor antibodies of this invention can be produced as described in U.S. Patent Application Serial Number 151,450; Fanger et al., "Monoclonal Antibodies to Fc Receptors for Immunoglobulin G on Human Mononuclear Phagocytes", the teachings of which are incorporated by reference herein.

The binding specificity for the pathogen component can be any binding agent specific for an antigen of the pathogen. For example, if the targeted pathogen is a virus, viral antigens such as those associated with Epstein Barr virus (EBV glycoprotein: M. Mackett and J.R. Arrand, EMBO J., 4: 3229-3234 (1985)); human Influenza virus (Haemagglutinin: E.B. Stephens et al., EMBO J., 5: 237-245 (1986)); hepatitis B virus (HBV major surface antigen: R.H. Purcell and J.L. Gerin, Am. J. ed. Sci., 270: 395-399 (1975)); and HIV (capsid env glycoproteins: A.S. Fauci, Science, 239: 617-622 (1988)) can be used as the source of viral target antigen needed to produce the binding specificity for molecules of this invention.

In preferred embodiments for HIV treatment, the HIV component is the envelope glycoprotein gp120 of HIV, found in the viral envelope and in cells harboring infectious HIV. The bispecific molecules are specific for gp120 and the HIV-binding agent can be provided by naturally-occurring or recombinant forms of the CD4 receptor of T cells or by the HIV binding domain of CD4. It is well known that CD4, expressed on T-lymphocytes, is the receptor for the

-6-

HIV envelope glycoprotein gp120. The CD4 protein is also the primary receptor for HIV entry into host cells, and for membrane fusion which contributes to cell-to-cell transmission of HIV and to its cytopathic effects. Maddon, P.J. *et al.*, Cell, 47: 333-348 (1986). Since the CD4 antigen was identified as the cell-surface receptor for HIV, it has been repeatedly shown that soluble forms of CD4 antigen can block the infectivity of the virus. Trauneker, A. *et al.*, Nature, 331: 84-86 (1988). Soluble CD4 inhibits diverse variants of HIV, indicating that all these viruses may share a relatively conserved CD4-binding region.

Soluble CD4 analogs or CD4 fragment with an affinity for gp120 comparable to that of intact CD4 can be prepared using methods described in the art. See, for example, Berger, E.A. *et al.*, Proc. Nat'l. Acad. Sci. USA, 85: 2357-2361 (1988); Arthos, J., *et al.*, Cell, 57: 469-481 (1989). Soluble CD4 fragments lack the hydrophobic transmembrane portion or contain only a small fraction of this transmembrane portion. Soluble CD4 fragments and CD4 analogs can be produced by inserting truncated CD4-encoding cDNA into expression vectors. CD4 polypeptide can be produced by such cells and the soluble CD4 can be tested for its ability to bind gp120 using standard coimmunoprecipitation assays. See, for example Smith, D.H. *et al.*, Science 238, 1704-1707 (1987).

Alternatively, the HIV binding specificity of the molecules of this invention can be provided by

-7-

anti-gp120 antib dies. These antib dies can also be produced by conventional monoclonal antibody methodology, e.g. the standard somatic cell hybridization technique of Kohler and Milstein, Nature, 256, 495
05 (1975), using the gp120 glycoprotein, or fragments thereof, as the immunogen. In brief, an animal such as a mouse is immunized with gp120 of HIV. The gp120 can be purified, or partially purified from viral lysates for this purpose. The purification of
10 gp120 can be accomplished by affinity chromatography with antibody against gp120. After immunization, B cells are taken from the immunized animal and then fused with an immortalizing cell such as a myeloma cell. See, for example, M.S.C. Fung et al.,
15 Biotechnology, 5: 940-946 (1987). It will be appreciated that subunits of gp120 can also be employed as the HIV component to which a binding specificity is provided. For example, antibodies can be prepared against the gp41 transmembrane
20 protein as well as smaller gene products of the envelope gene of HIV. See, for example, W.G. Robey et al., Science 228, 593-595 (1985).

Bispecific molecules of this invention can also be prepared by conjugating a binding specificity for
25 a pathogen (i.e. virus or viral antigen) to an anti-Fc γ receptor (Fc γ R) gene. Development and cloning of the gene for the binding site of anti-Fc γ R, is well within the capabilities of those skilled in the art. This gene could be linked to
30 genes encoding viral receptors such as the CD4 molecule. Such constructs can be used to target

- 8 -

viral infectious agents and infected cells through FcγR.

05 The bispecific molecules of this invention can be of several configurations. Bispecific antibodies are single antibodies (or antibody fragments) which have two different antigen binding sites (variable regions). Bispecific antibodies of this invention have one binding site for Fcγ receptor and one binding site for a viral epitope. Bispecific
10 antibodies can be produced by chemical techniques (see e.g., Kranz, D. M. et al., Proc. Natl. Acad. Sci. USA 78,5807 (1981)) by "polydoma" techniques (see U.S. Patent 4,474,893, to Reading) or by recombinant DNA techniques.

15 Heteroantibodies are two or more antibodies, or antibody binding fragments (Fab) linked together, each antibody or fragment having a different specificity. Bivalent heteroantibodies of this invention comprise an antibody (or fragment) specific for Fcγ
20 receptor, coupled to an antibody (or fragment) specific for a viral epitope. Heteroantibodies can be prepared by conjugating Fcγ receptor antibody with antibody specific for an epitope of the HIV envelope glycoprotein gp120. A variety of coupling
25 or crosslinking agents can be used to conjugate the antibodies. Examples are protein A, carboiimide, dimaleimide, dithio-bis-nitrobenzoic acid (DTNB), and N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP). SPDP and DTNB are the preferred agents;
30 procedures for crosslinking antibodies with these

- 9 -

agents are known in the art. See e.g., Karpovsky, B. et al., (1984) J. Exp. Med. 160:1686; Liu, M.A. et al., (1985) Proc. Natl. Acad. Sci USA 82:8648; Segal, D.M. and Perez, P., U.S. Patent No. 4,676,980 (June 30, 1987); and Brennan, M. Biotechniques 4:424 (1986).

The bispecific molecules of this invention can also be prepared as recombinant molecules. Constructs can be developed that comprise genes encoding viral receptors linked to genes encoding the binding site (variable region) of anti-Fc γ R antibody. Thus, a recombinant nucleic acid which encodes a molecule having dual specificity can be prepared by linking a gene encoding a receptor for a viral antigen (e.g. a cell-surface receptor such as CD4 which binds to gp120 on HIV or HIV-infected cells) to the gene encoding either the light or heavy chain variable region of an anti-Fc γ R antibody. These genetic constructs, or other constructs linking genes for different viral receptors to the anti-Fc γ R antibody gene, can be expressed in suitable host cells.

Bispecific molecules of this invention can be administered to target the killing of virus and virally infected cells. The molecules can be given in free form. Alternatively, the molecules can be attached to the surface of effector cells in vitro and the cells can be administered. In each mode the principle is the same; the effector cell is targeted toward the virus.

Effector cells for targeting are human leukocytes, preferably macrophages. Other cells can

-10-

include monocytes, activated neutrophils, and possibly activated natural killer (NK) cells and eosinophils. Macrophages can be treated with IFN- γ before targeting to increase the number of Fc
05 receptors for attachment of the targeting antibody or heteroantibody. Neutrophils and NK cells can also be activated with IFN- γ in this way. The effector cells may also be activated before
10 targeting by other cytokines such as tumor necrosis factor, lymphotoxin, colony stimulating factor, and interleukin-2. If desired, effector cells for targeting can be obtained from the host to be treated, or any other immunologically-compatible donor.

15 The targeted effector cells can be administered as a suspension of cells in a physiologically acceptable solution. The number of cells administered can be in the order of 10^8 - 10^9 , but will vary depending on the therapeutic purpose. In general,
20 the amount will be sufficient to obtain localization of the effector cell at the target cell or pathogen, and to effect killing of the cell or pathogen by antibody dependent cell-mediated cytotoxicity (ADCC) and/or phagocytosis. Routes of administration can
25 also vary. The targeted effector cells could be administered intravenously, intramuscularly, or intraperitoneally.

Bispecific molecules of this invention link viral-specific binding agents to Fc γ R on effector
30 cells in such a way that the large excess of human IgG in vivo does not interfere with binding of the molecule to effector cells or interfere with

-11-

functioning of effector cells. This is possible because the anti-Fc γ R component of these molecules binds to Fc γ R at an epitope outside of its ligand binding domain. Effector cells (i.e. macrophages) targeted in this way can be employed to bring about antibody-dependent cell-mediated killing of HIV or HIV-infected cells.

The bispecific molecules of this invention have a potentially long half-life in vivo. This can result from the interaction of these constructs with Fc γ R on all monocytes and macrophages where it might remain for long periods of time, much of it out of circulation, but functionally active throughout the body on all cells of the reticuloendothelial system.

Bivalent bispecific molecules of this invention can be more sensitive to triggering than other constructs because of their bivalent nature. This is because internalization of the construct and killing of the targeted infectious agent requires receptor crosslinking. A bivalent bispecific complex will initiate cross-linking more efficiently than a monovalent bispecific construct. Furthermore, the binding avidity of a bivalent bispecific construct is likely to be greater than a monovalent bispecific molecule, and therefore be more effective in clearing HIV and HIV-infected cells. This is an important advantage of a bivalent bispecific molecule. A monovalent molecule comprising, for example, the Fc region of IgG complexed with a viral binding specificity (Capon, D.J. et al., supra) will bind to only one Fc γ RI molecule since only one of

-12-

th Fc regions of an antibody can bind to the high-affinity Fc γ RI receptor. Constructs of this invention having bivalent bispecific or heteroantibody configurations offer an advantage since they can be manipulated to provide greater avidity or triggering capability.

The bispecific molecules of this invention are specific for interaction with only Fc γ RI. Constructs employing the Fc domain of IgG (Capon, D.J. et al., supra) interact with all three types of Fc receptor. This lack of specificity may be of considerable disadvantage since Fc γ RII and Fc γ RIII are expressed by other cells besides monocytes, such as B-cells, platelets, and placental Ig transfer cells. Thus, there is the possibility that HIV may be introduced through Fc γ RII and/or Fc γ RIII into cells that cannot kill but which may harbor the virus. Moreover, Fc γ RI has been found to be a killing receptor on all cell populations on which it has been found. In contrast, the other two Fc receptors only function as cytotoxic trigger molecules on some of the cells on which they are expressed, and then only under some conditions.

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such

-13-

equivalents are intended to be encompassed by the following claims.

-14-

CLAIMS

- 05 1. A bispecific molecule having a binding specificity for a pathogen or pathogen component and a binding specificity for the high-affinity Fc γ receptor, the binding of which to the Fc γ receptor is not blocked by human immunoglobulin G.
- 10 2. A bispecific molecule of Claim 1, wherein the pathogen or pathogen component is a virus or viral component.
3. A bispecific molecule of Claim 2, wherein the virus is human immunodeficiency virus (HIV).
- 15 4. A bispecific molecule of Claim 3, wherein the virus component is the envelope glycoprotein gp120 of HIV or a fragment thereof.
5. A bispecific molecule of Claim 3, wherein the virus component is the envelope glycoprotein gp41 of HIV.
- 20 6. A bispecific molecule of Claim 4, wherein the binding specificity for the virus component gp120 is provided by the CD4 receptor of T-cells or the gp120 binding domain thereof.
7. A bispecific molecule of Claim 4, wherein

-15-

the binding specificity for the virus component gp120 is provided by an gp120-specific antibody or fragment thereof.

- 05 8. A bispecific molecule of Claim 1, which is a bispecific antibody.
9. A bispecific molecule of Claim 1, which is an aggregate of two or more antibodies or fragments thereof.
- 10 10. A bispecific molecule of Claim 1 which is a recombinant molecule.
- 15 11. A bispecific molecule comprising a specific binding agent for human immunodeficiency virus (HIV) and a specific binding agent for the high affinity Fcγ receptor for IgG on human monocytes, the binding site for the agent on the high-affinity Fcγ receptor being distinct from the ligand binding site of the receptor for Fc.
- 20 12. A bispecific molecule of Claim 11, wherein the specific binding agent for HIV binds to the envelope glycoprotein gp120 or a fragment thereof.
- 25 13. A bispecific molecule of Claim 11, wherein the specific binding agent for HIV binds to the envelope glycoprotein gp41 of HIV.

-16-

14. A bispecific molecule of Claim 11, wherein the specific binding agent is the CD4 receptor of T-cells.
- 05 15. A bispecific molecule of Claim 11, wherein the specific binding agent is anti-gp120 antibody.
- 10 16. A bispecific reagent, comprising a CD4 receptor linked to an antibody or fragment thereof specific for an epitope of the high affinity Fc γ receptor, the epitope being outside of the ligand binding domain for Fc of the receptor and the binding of which to the Fc receptor is not blocked by human immunoglobulin G.
- 15 17. A heteroantibody, comprising:
 - a. an antibody or antibody binding fragment specific for the envelope gp120 glycoprotein of the HIV virus; and
 - 20 b. an antibody or antibody binding fragment specific for the high-affinity Fc γ receptor for IgG on human effector cells, the binding of which to the human Fc receptor of the effector cells is not blocked by human immunoglobulin G.
- 25 18. A heteroantibody of Claim 17, wherein the effector cell is selected from the group consisting of monocytes, macrophages, neutrophils and eosinophils.

-17-

19. A target-specific effector cell, comprising:
- a. an effector cell expressing high affinity receptor for the Fc portion of IgG; and
 - b. a bispecific molecule bound to an epitope of the Fc receptor of the effector cell that is outside of the ligand binding domain of the receptor, the molecule comprising:
 - (i) at least one binding specificity for a virus or virus component; and
 - (ii) at least one binding specificity for the high-affinity Fc γ receptor, the binding of which to the Fc receptor of the effector cell is not blocked by human immunoglobulin G.
20. A target-specific effector cell of Claim 19, wherein the effector cell is a human monocyte or macrophage.
- 20 21. A target-specific effector cell of Claim 19, wherein the virus is human immunodeficiency virus (HIV).
22. A target specific effector cell of Claim 19, wherein the virus component is envelope glycoprotein gp120 of HIV.
- 25 23. A target specific effector cell of Claim 19, wherein the virus component is the envelope

-18-

glycoprot in gp41 of HIV.

- 05 24. A target specific effector cell of Claim 22, wherein the binding specificity for a virus component is provided by the CD4 region of T-cells or the gp120 binding domain thereof.
25. A target-specific effector cell of Claim 22 wherein the binding specificity for a virus component is provided by an gp120-specific antibody or fragment thereof.
- 10 26. A target-specific effector cell of Claim 19, wherein the bispecific molecule is a bispecific antibody.
- 15 27. A target-specific effector cell of Claim 19, wherein the bispecific molecule is an aggregate of two antibodies or fragments thereof.
- 20 28. A method of treating viral infection, comprising administering to a patient afflicted with a viral infection, a therapeutic amount of targeted effector cells, each targeted effector cell comprising:
- 25 a. an effector cell expressing receptor for the Fc portion of IgG complexed with a;
- b. bispecific molecule bound to the Fc receptor of the effector cell, the bispecific molecule comprising:

-19-

- (i) at least one binding specificity
for a virus or virus component;
and
- 05 (ii) at least one binding specificity
for the high-affinity Fc γ
receptor on the effector
cell, the binding of which to the
Fc receptor of the effector cell
is not blocked by human
10 immunoglobulin G and which binds
to an epitope on the Fc receptor
of the effector cell that
is outside of its ligand binding
domain.
- 15 29. A method of Claim 28, wherein the virus is the
human immunodeficiency virus (HIV).
30. A method of Claim 28, wherein the virus
component is the envelope glycoprotein gp120 of
HIV.
- 20 31. A method of Claim 28, wherein the virus
component is the envelope glycoprotein gp41 of
HIV.
- 25 32. A method of Claim 30, wherein the binding
specificity for the virus component is provided
by the CD4 receptor of T-cells or the gp120
binding domain thereof.

-20-

33. A method of Claim 30, wherein the binding specificity for the virus component is provided by an gp120-specific antibody or fragment thereof.
- 05 34. A method of Claim 28, wherein the bispecific molecule is a bispecific antibody.
35. A method of Claim 28, wherein the bispecific molecule is an aggregate of two or more antibodies or fragments thereof.
- 10 36. A method of Claim 28, wherein the effector cell is a human monocyte or macrophage.
37. A method of treating viral infection in a patient, comprising administering to a patient afflicted with a viral infection a therapeutic amount of a bispecific molecule, the molecule comprising:
- 15 (i) at least one binding specificity for a virus or virus component; and
- 20 (ii) at least one binding specificity for the high-affinity Fc γ receptor on the effector cell, the binding of which to the Fc receptor of the effector cell is not blocked by human immunoglobulin G and which binds to an epitope on the Fc receptor of the
- 25 effector cell that is outside of its ligand binding domain.

-21-

38. A method of Claim 37, wherein the virus is the human immunodeficiency virus (HIV).
- 05 39. A method of Claim 37, wherein the virus component is the envelope glycoprotein gp120 of HIV.
40. A method of Claim 37, wherein the virus component is the envelope glycoprotein gp41 of HIV.
- 10 41. A method of Claim 39, wherein the binding specificity for the virus component is provided by the CD4 receptor of T-cells or the gp120 binding domain thereof.
- 15 42. A method of Claim 39, wherein the binding specificity for the virus component is provided by an gp120-specific antibody or fragment thereof.
43. A method of Claim 37, wherein the bispecific molecule is a bispecific antibody.
- 20 44. A method of Claim 37, wherein the bispecific molecule is an aggregate of two or more antibodies or fragments thereof.

INTERNATIONAL SEARCH REPORT

International Application No **PCT/US 90/03751**

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC⁵: C 12 P 21/00, C 12 N 5/00, A 61 K 39/395																	
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 25%; border-bottom: 1px solid black;">Classification System</th> <th style="border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="border: 1px solid black; padding: 5px; vertical-align: top;">IPC⁵</td> <td style="border: 1px solid black; padding: 5px; vertical-align: top;">C 12 P, C 07 K</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸</div>			Classification System	Classification Symbols	IPC ⁵	C 12 P, C 07 K											
Classification System	Classification Symbols																
IPC ⁵	C 12 P, C 07 K																
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border-bottom: 1px solid black;">Category ⁹</th> <th style="border-bottom: 1px solid black;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 15%; border-bottom: 1px solid black;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="border: 1px solid black; padding: 5px;"> WO, A, 88/00052 (TRUSTEES OF DARTMOUTH COLLEGE) 14 January 1988 see page 8, line 15 - page 17, line 2 <div style="text-align: center;">--</div> </td> <td style="border: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">1-27</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="border: 1px solid black; padding: 5px;"> EP, A, 0308936 (BRISTOL-MYERS COMPANY) 29 March 1989 see page 4, line 50 - page 7, line 27 <div style="text-align: center;">--</div> </td> <td style="border: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">1-27</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="border: 1px solid black; padding: 5px;"> Letters to Nature, volume 339, 4 May 1989, A. Trauneker et al.: "Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules", pages 68-70 see the whole article <div style="text-align: center;">--</div> </td> <td style="border: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">1-27</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="border: 1px solid black; padding: 5px;"> GB, A, 2197323 (NATIONAL RESEARCH DEVELOPMENT CORPORATION) <div style="text-align: right;">./.</div> </td> <td style="border: 1px solid black;"></td> </tr> </table>			Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	Y	WO, A, 88/00052 (TRUSTEES OF DARTMOUTH COLLEGE) 14 January 1988 see page 8, line 15 - page 17, line 2 <div style="text-align: center;">--</div>	1-27	Y	EP, A, 0308936 (BRISTOL-MYERS COMPANY) 29 March 1989 see page 4, line 50 - page 7, line 27 <div style="text-align: center;">--</div>	1-27	Y	Letters to Nature, volume 339, 4 May 1989, A. Trauneker et al.: "Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules", pages 68-70 see the whole article <div style="text-align: center;">--</div>	1-27	A	GB, A, 2197323 (NATIONAL RESEARCH DEVELOPMENT CORPORATION) <div style="text-align: right;">./.</div>	
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³															
Y	WO, A, 88/00052 (TRUSTEES OF DARTMOUTH COLLEGE) 14 January 1988 see page 8, line 15 - page 17, line 2 <div style="text-align: center;">--</div>	1-27															
Y	EP, A, 0308936 (BRISTOL-MYERS COMPANY) 29 March 1989 see page 4, line 50 - page 7, line 27 <div style="text-align: center;">--</div>	1-27															
Y	Letters to Nature, volume 339, 4 May 1989, A. Trauneker et al.: "Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules", pages 68-70 see the whole article <div style="text-align: center;">--</div>	1-27															
A	GB, A, 2197323 (NATIONAL RESEARCH DEVELOPMENT CORPORATION) <div style="text-align: right;">./.</div>																
⁹ Special categories of cited documents: ¹⁰ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "A" document member of the same patent family															
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;"> Date of the Actual Completion of the international Search <div style="text-align: center; margin-top: 10px;">23rd October 1990</div> </td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;"> Date of Mailing of this International Search Report <div style="text-align: center; margin-top: 10px;">1,2 NOV. 1990</div> </td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;"> International Searching Authority <div style="text-align: center; margin-top: 10px;">EUROPEAN PATENT OFFICE</div> </td> <td style="border-bottom: 1px solid black; padding: 5px;"> Signature of Authorized Officer <div style="text-align: center; margin-top: 10px;"> MISS T. TAZELAAR </div> </td> </tr> </table>			Date of the Actual Completion of the international Search <div style="text-align: center; margin-top: 10px;">23rd October 1990</div>	Date of Mailing of this International Search Report <div style="text-align: center; margin-top: 10px;">1,2 NOV. 1990</div>	International Searching Authority <div style="text-align: center; margin-top: 10px;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center; margin-top: 10px;"> MISS T. TAZELAAR </div>											
Date of the Actual Completion of the international Search <div style="text-align: center; margin-top: 10px;">23rd October 1990</div>	Date of Mailing of this International Search Report <div style="text-align: center; margin-top: 10px;">1,2 NOV. 1990</div>																
International Searching Authority <div style="text-align: center; margin-top: 10px;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center; margin-top: 10px;"> MISS T. TAZELAAR </div>																

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

18 May 1988

--

A

GB, A, 2197322 (NATIONAL RESEARCH
DEVELOPMENT CORPORATION)
18 May 1988

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers 28-44 because they relate to subject matter not required to be searched by this Authority, namely:

see PCT-rule 39.1(IV):

methods for treatment of the human or animal body by surgery
or therapy, as well as diagnostic methods.

2. ☐ Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9003751

SA 38715

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 05/11/90. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A- 8800052	14-01-88	AU-A- 7527187	14-01-88
		EP-A- 0255249	03-02-88
		JP-T- 1500195	26-01-89
EP-A- 0308936	29-03-89	AU-A- 2279988	23-03-89
		JP-A- 1163134	27-06-89
GB-A- 2197323	18-05-88	AU-A- 8156887	01-06-88
		EP-A- 0293405	07-12-88
		WO-A- 8803566	19-05-88
		JP-T- 1501201	27-04-89
GB-A- 2197322	18-05-88	AU-A- 8156987	01-06-88
		EP-A- 0289546	09-11-88
		WO-A- 8803565	19-05-88
		JP-T- 1501200	27-04-89